Clinical Trial Detail

NCT ID NCT03904069
Title Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Amgen
Indications

acute myeloid leukemia

Therapies

Anti-FLT3 CAR-T cells

Age Groups: adult senior child

Additional content available in CKB BOOST